Corcept Therapeutics | CORT - Debt


Corcept Therapeutics reported $9.64M in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
Acadia Pharmaceuticals USD 50.79M 1.39M Mar/2026
Alaunos Therapeutics USD 10.99M 5.78M Mar/2023
ANI Pharmaceuticals USD 617.04M 3.28M Dec/2025
Ardelyx USD 208.26M 653K Mar/2026
Aurora Cannabis CAD 23.86M 76.48M Mar/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Canopy Growth CAD 278.71M 19.38M Mar/2026
Corcept Therapeutics USD 9.64M 3.53M Mar/2026
Eli Lilly USD 43.37B 867M Mar/2026
J&J USD 54.99B 7.05B Mar/2026
Knight Therapeutics CAD 77.91M 28.33M Dec/2025
Lexicon Pharmaceuticals USD 99.51M 243K Dec/2023
Merck USD 49.12B 222M Mar/2026
Nektar Therapeutics USD 0 0 Jun/2022
Novartis USD 49.01B 2.02B Jun/2026
Novartis USD 47B 14.98B Mar/2026
Omeros USD 442.16M 199K Sep/2023
Pacira USD 363.12M 4.53M Jun/2026
Pfizer USD 63.73B 231M Mar/2026
Supernus Pharmaceuticals USD 40.9M 74K Mar/2026
TG Therapeutics USD 753.56M 499.85M Mar/2026